GSK plc (NYSE:GSK) Shares Acquired by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. increased its position in GSK plc (NYSE:GSK) by 5.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 176,482 shares of the pharmaceutical company’s stock after buying an additional 9,777 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in GSK were worth $6,540,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in GSK. Simmons Bank grew its stake in shares of GSK by 3.1% during the fourth quarter. Simmons Bank now owns 138,714 shares of the pharmaceutical company’s stock valued at $5,141,000 after acquiring an additional 4,130 shares in the last quarter. Apollon Wealth Management LLC grew its stake in GSK by 86.2% during the 4th quarter. Apollon Wealth Management LLC now owns 19,760 shares of the pharmaceutical company’s stock valued at $732,000 after purchasing an additional 9,145 shares in the last quarter. Lincoln National Corp increased its holdings in GSK by 11.7% during the 4th quarter. Lincoln National Corp now owns 14,895 shares of the pharmaceutical company’s stock worth $552,000 after purchasing an additional 1,560 shares during the last quarter. Royal Fund Management LLC raised its position in shares of GSK by 4.6% in the 4th quarter. Royal Fund Management LLC now owns 24,389 shares of the pharmaceutical company’s stock valued at $904,000 after purchasing an additional 1,065 shares in the last quarter. Finally, Legacy Financial Advisors Inc. purchased a new position in shares of GSK during the 4th quarter valued at approximately $259,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on GSK shares. Morgan Stanley assumed coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Finally, Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

GSK Price Performance

Shares of NYSE:GSK opened at $44.15 on Thursday. The stock has a market capitalization of $91.49 billion, a price-to-earnings ratio of 15.99, a price-to-earnings-growth ratio of 1.85 and a beta of 0.65. GSK plc has a 1-year low of $33.33 and a 1-year high of $44.33. The company’s fifty day moving average is $41.93 and its two-hundred day moving average is $39.30. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.41%. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio is presently 53.26%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.